Background
Material and methods
Patients and study design
Statistical analysis
Results
Clinical characteristics of subjects
Variables | |
---|---|
Number of patients | 146 |
Mini-mental state examination score | 27.8 ± 3.1 |
Male, n (%) | 111 (76.0%) |
Age, y | 70.9 ± 8.6 |
Body mass index, kg/m2
| 23.5 ± 3.4 |
Systolic blood pressure, mmHg | 127 ± 16.3 |
Diastolic blood pressure, mmHg | 71 ± 11.6 |
Low-density lipoprotein cholesterol, mg/dL | 96.0 ± 34.4 |
Triglycerides, mg/dL | 124.5 ± 70.3 |
High-density lipoprotein cholesterol, mg/dL | 55.0 ± 14.7 |
HbA1c, % | 6.7 ± 5.5 |
Fasting plasma blood glucose, mg/dL | 130.0 ± 58.7 |
Brain natriuretic peptide, pg/mL | 151.6 ± 274.2 |
Left ventricular ejection fraction, % | 58.6 ± 11.2 |
Fatty acids | |
Docosahexaenoic acid, μg/mL | 132.5 ± 52.2 |
Eicosapentaenoic acid, μg/mL | 68.9 ± 40.4 |
Arachidonic acid, μg/mL | 173.0 ± 43.4 |
Dihomogammalinolenic acid, μg/mL | 34.5 ± 11.4 |
Complications | |
Dyslipidemia, n (%) | 126 (86.3%) |
Hypertension, n (%) | 131 (89.7%) |
Diabetes mellitus, n (%) | 80 (54.8%) |
Cerebrovascular disease, n (%) | 25 (17.1%) |
Smoking, n (%) | 108 (74.0%) |
Drugs | |
ACEI/ARB, n (%) | 91 (62.3%) |
β-blockers, n (%) | 53 (36.3%) |
Calcium channel blockers, n (%) | 62 (42.5%) |
Statins, n (%) | 123 (84.2%) |
Ezetimibe, n (%) | 8 (5.5%) |
Diuretics loop, n (%) | 27 (18.5%) |
Mineralocorticoid antagonists, n (%) | 7 (4.8%) |
Correlation between n-3 PUFAs and MMSE score
Variables | R | P-value |
---|---|---|
Age | −0.20 | < 0.01 |
Sex | - | 0.30 |
Body mass index | 0.09 | 0.23 |
DHA | 0.12 | 0.06 |
EPA | 0.25 | <0.01 |
AA | 0.1 | 0.99 |
DGLA | −0.001 | 0.20 |
EPA/AA | 0.22 | 0.01 |
DHA/AA | 0.10 | 0.20 |
Left ventricular ejection fraction | 0.15 | 0.04 |
Brain natriuretic peptide | −0.28 | < 0.01 |
Hypertension | - | 0.96 |
Dyslipidemia | - | 0.89 |
Diabetes mellitus | - | 0.37 |
Cerebrovascular disease | - | 0.79 |
Current/previous smoker | - | 0.12 |
Variables | Coefficient | 95% confidence interval | P-value |
---|---|---|---|
Model 1
| |||
Age, years | −0.004 | −0.007 to −0.001 | 0.02 |
Male sex | 0.005 | −0.03 to 0.04 | 0.76 |
Body mass index, kg/m2
| −0.0008 | −0.001 to 0.007 | 0.85 |
Hypertension | 0.02 | −0.01 to 0.06 | 0.24 |
Dyslipidemia | −0.001 | −0.04 to 0.03 | 0.91 |
Diabetes mellitus | 0.001 | −0.02 to 0.02 | 0.98 |
Cerebrovascular disease | −0.01 | −0.04 to 0.02 | 0.50 |
Current/previous smoker | 0.001 | −0.03 to 0.04 | 0.80 |
EPA, μg/mL | 0.001 | 0.0003 to 0.002 | < 0.01 |
DHA, μg/mL | −0.0004 | −0.001 to 0.0003 | 0.22 |
AA, μg/mL | 0.0001 | −0.0001 to 0.001 | 0.83 |
DGLA, μg/mL | 0.001 | −0.002 to 0.004 | 0.45 |
LVEF, % | 0.001 | −0.001 to 0.004 | 0.20 |
BNP, pg/mL | −0.015 | −0.035 to 0.005 | 0.15 |
Model 2
| |||
Age, years | −0.003 | −0.006 to −0.0002 | 0.04 |
Male sex | 0.002 | −0.03 to 0.04 | 0.89 |
Body mass index, kg/m2
| 0.0008 | −0.006 to 0.008 | 0.83 |
Hypertension | 0.02 | −0.02 to 0.05 | 0.37 |
Dyslipidemia | 0.003 | −0.03 to 0.04 | 0.84 |
Diabetes mellitus | 0.002 | −0.03 to 0.04 | 0.85 |
Cerebrovascular disease | −0.01 | −0.03 to 0.02 | 0.58 |
Current/previous smoker | 0.003 | −0.03 to 0.04 | 0.85 |
EPA/AA | 0.15 | 0.03 to 0.28 | 0.01 |
DHA/AA | −0.04 | −0.15 to 0.07 | 0.42 |
LVEF, % | 0.001 | −0.001 to 0.003 | 0.29 |
BNP, pg/mL | −0.018 | −0.04 to 0.001 | 0.06 |